Form 990 for tax year 2023
Filed by JAEB CENTER FOR HEALTH RESEARCH INC.
Totals
- Total revenue
- $53,220,979
- Total expenses
- $44,888,416
- Contributions and grants received
- $35,083,784
- Grants paid
- $911,714
- Program service revenue
- $17,927,381
- Investment income
- $209,814
- Other revenue
- $0
- Total assets, end of year
- $23,767,716
- Total liabilities, end of year
- $19,487,316
- Net assets or fund balances, end of year
- $4,280,400
- Program services expenses (Part IX)
- $37,585,083
- Management and general expenses
- $7,303,333
- Fundraising expenses
- $0
- Program service expenses (Part III)
- $37,585,083
Program services were 83.7% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1d · Related organizations
$6,177,957
-
1e · Government grants (contributions)
$18,644,335
-
1f · All other contributions, gifts and grants
$10,261,492
-
2a · Program service revenue: INDUSTRY PROGRAM SERVICE EXCHANGE
total $17,927,381 · related or exempt $17,927,381
-
3 · Investment income
total $206,410 · excluded $206,410
-
7a · Gross sales of assets other than inventory
securities $2,283,000
-
7b · Less cost or other basis and sales expenses
securities $2,279,596
-
7c · Gain or loss
securities $3,404
-
7d · Net gain or loss
total $3,404 · excluded $3,404
Functional expenses
Part IX, the statement of functional expenses.
-
1 · Grants to domestic organizations and governments
total $911,714 · program services $911,714
-
5 · Compensation of officers, directors and key employees
total $1,401,020 · program services $412,463 · management and general $988,557
-
7 · Other salaries and wages
total $12,636,855 · program services $9,409,039 · management and general $3,227,816
-
8 · Pension plan contributions
total $1,950,641 · program services $1,395,712 · management and general $554,929
-
9 · Other employee benefits
total $1,341,277 · program services $979,772 · management and general $361,505
-
10 · Payroll taxes
total $1,099,269 · program services $773,683 · management and general $325,586
-
11b · Fees: legal
total $25,187 · management and general $25,187
-
11c · Fees: accounting
total $125,887 · management and general $125,887
-
11f · Fees: investment management
total $3,813 · management and general $3,813
-
11g · Fees: other
total $1,040,420 · program services $933,222 · management and general $107,198
-
12 · Advertising and promotion
total $1,202 · management and general $1,202
-
13 · Office expenses
total $32,360 · management and general $32,360
-
14 · Information technology
total $651,967 · program services $1,152 · management and general $650,815
-
16 · Occupancy
total $507,952 · management and general $507,952
-
17 · Travel
total $1,000,683 · program services $964,533 · management and general $36,150
-
22 · Depreciation, depletion and amortization
total $109,083 · management and general $109,083
-
23 · Insurance
total $135,013 · management and general $135,013
-
24a · Other expenses: SUBCONTRACTOR PAYMENTS
total $18,433,305 · program services $18,433,305
-
24b · Other expenses: RESEARCH EXPENSES
total $3,321,200 · program services $3,321,200
-
24c · Other expenses: TRAINING
total $53,457 · program services $1,350 · management and general $52,107
-
24d · Other expenses: DUES & SUBSCRIPTIONS
total $37,697 · management and general $37,697
-
24e · All other expenses
total $68,414 · program services $47,938 · management and general $20,476
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $4,590,445 · end of year $9,063,779
-
2 · Savings and temporary cash investments
beginning of year $0 · end of year $2,633,881
-
3 · Pledges and grants receivable
beginning of year $5,073,199 · end of year $7,699,495
-
4 · Accounts receivable
beginning of year $0 · end of year $12,138
-
9 · Prepaid expenses and deferred charges
beginning of year $183,416 · end of year $464,581
-
10a · Land, buildings and equipment: cost or other basis
$1,280,054
-
10b · Land, buildings and equipment: accumulated depreciation
$1,041,604
-
10c · Land, buildings and equipment, net
beginning of year $149,921 · end of year $238,450
-
11 · Investments: publicly traded securities
beginning of year $0 · end of year $2,574,929
-
15 · Other assets
beginning of year $452,137 · end of year $1,080,463
-
17 · Accounts payable and accrued expenses
beginning of year $1,406,415 · end of year $4,597,583
-
19 · Deferred revenue
beginning of year $12,707,254 · end of year $13,768,197
-
25 · Other liabilities
beginning of year $425,060 · end of year $1,121,536
-
27 · Net assets without donor restrictions
beginning of year -$4,089,611 · end of year $4,280,400
Mission and programs · 2023
Mission
OUR MISSION IS TO EXPAND SCIENTIFIC KNOWLEDGE AND IMPROVE PUBLIC HEALTH BY DESIGNING AND CONDUCTING WORLD-CLASS CLINICAL TRIALS AND EPIDEMIOLOGIC RESEARCH.
Activities or mission (Part I)
DESIGN AND CONDUCT WORLD-CLASS CLINICAL TRIALS AND EPIDEMIOLOGIC RESEARCH.
-
SEE SCHEDULE O DURING 2023, JCHR WAS ENGAGED IN 53 CLINICAL STUDIES. THESE STUDIES RESULTED IN 42 SCIENTIFIC PUBLICATIONS AND 59 PRESENTATIONS AT NATIONAL AND INTERNATIONAL MEETINGS.IN 2023, JCHR RECEIVED GRANTS FROM THE NATIONAL INSTITUTES OF HEALTH (8), HELMSLEY CHARITABLE TRUST (8), JDRF (6), FOUNDATION FIGHTING BLINDNESS (5), CYSTIC FIBROSIS FOUNDATION (4), AND FOOD AND DRUG ADMINISTRATION (1). COLLABORATIONS WITH INDUSTRY CONTINUE TO FORM AN INTEGRAL PART OF OUR BUSINESS. JCHR WAS ENGAGED IN STRATEGIC COLLABORATIONS WITH 10 INDUSTRY PARTNERS IN 2023. THESE COLLABORATIONS SPANNED 15 STUDIES. SEVERAL STUDIES ARE FUNDED BY MULTIPLE SOURCES. FOR EXAMPLE, ONE CLINICAL TRIAL EVALUATING FENOFIBRATE FOR DIABETIC RETINOPATHY IS A LARGE COLLABORATION WITH FUNDS PROVIDED BY THE NATIONAL INSTITUTES OF HEALTH (NATIONAL EYE INSTITUTE AND NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASE), JDRF, HELMSLEY CHARITABLE TRUST, AND ROCHE. JCHR ALSO SELF-FUNDED TWO STUDIES AND NUMEROUS STATISTICAL ANALYSIS PROJECTS USING DATASETS FROM PREVIOUSLY COMPLETED STUDIES. AMONG 2,894 ENTITIES RECEIVING NIH FUNDING IN 2023, JCHR RANKS IN THE TOP 8 PERCENT. OUT OF 66,149 NIH GRANTS PROVIDED IN 2023, JCHR HAD THE 136TH- (TOP 0.2 PERCENT) AND 210TH- (TOP 0.3 PERCENT) LARGEST GRANTS (SOURCE: BLUE RIDGE INSTITUTE FOR MEDICAL RESEARCH, 2023).IN 2023, THE JCHR COORDINATED RANDOMIZED TRIAL OF A BIONIC PANCREAS IN INDIVIDUALS WITH TYPE 1 DIABETES LEAD TO FDA 510(K) CLEARANCE FOR THE BETA BIONICS ILET BIONIC PANCREAS. IN ADDITION, RESULTS FROM THE DEXCOM SPONSORED MOBILE STUDY (COORDINATED BY JCHR) SERVED AS THE PRIMARY PIECE OF CLINICAL EVIDENCE THAT LED TO MEDICARE COVERAGE EXPANSION FOR CONTINUOUS GLUCOSE MONITORS, PROVIDING COVERAGE TO PEOPLE WITH DIABETES USING INSULIN, IRRESPECTIVE OF DIABETES TYPE.RESULTS FROM JCHR-AUTHORED MANUSCRIPTS INCLUDE THE FOLLOWING TWO THAT WERE PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE AND THREE PUBLISHED IN JAMA:A STUDY INVOLVING PREGNANT WOMEN WITH TYPE 1 DIABETES COMPARED THE EFFECTIVENESS OF STANDARD INSULIN THERAPY TO HYBRID CLOSED-LOOP THERAPY, WHICH USES CONTINUOUS GLUCOSE MONITORING. THE RESULTS SHOWED THAT THE CLOSED-LOOP THERAPY GROUP HAD SIGNIFICANTLY BETTER GLYCEMIC CONTROL DURING PREGNANCY COMPARED WITH THE STANDARD-CARE GROUP, WITH FEWER INSTANCES OF HYPERGLYCEMIA AND IMPROVED OVERNIGHT GLUCOSE LEVELS, INDICATING THE POTENTIAL BENEFITS OF THIS APPROACH FOR MANAGING TYPE 1 DIABETES DURING PREGNANCY.IN A 13-WEEK TRIAL INVOLVING YOUNG CHILDREN (AGED 2 TO UNDER 6 YEARS) WITH TYPE 1 DIABETES, A CLOSED-LOOP SYSTEM OF INSULIN DELIVERY WAS COMPARED WITH STANDARD CARE USING EITHER AN INSULIN PUMP OR MULTIPLE DAILY INJECTIONS WITH A CONTINUOUS GLUCOSE MONITOR. RESULTS SHOWED THAT CHILDREN USING THE CLOSED-LOOP SYSTEM SPENT SIGNIFICANTLY MORE TIME WITHIN THE TARGET RANGE COMPARED WITH THOSE IN THE STANDARD-CARE GROUP.IN A DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL INVOLVING CHILDREN AND ADOLESCENTS NEWLY DIAGNOSED WITH TYPE 1 DIABETES, THE EFFECTS OF VERAPAMIL, A CALCIUM CHANNEL BLOCKER, WERE INVESTIGATED ON PANCREATIC BETA CELL FUNCTION. PARTICIPANTS RECEIVING VERAPAMIL DEMONSTRATED A 30 PERCENT HIGHER C-PEPTIDE LEVEL AT 52 WEEKS COMPARED WITH THOSE ON A PLACEBO, INDICATING PARTIAL PRESERVATION OF PANCREATIC BETA CELL FUNCTION. FURTHER STUDIES ARE NEEDED TO ASSESS THE LONG-TERM DURABILITY OF C-PEPTIDE IMPROVEMENT AND DETERMINE THE OPTIMAL DURATION OF THERAPY. IN A RANDOMIZED, DOUBLE-BLIND CLINICAL TRIAL INVOLVING YOUTH WITH NEWLY DIAGNOSED TYPE 1 DIABETES, INTENSIVE DIABETES MANAGEMENT, INCLUDING THE USE OF AN AUTOMATED INSULIN DELIVERY SYSTEM, WAS COMPARED TO STANDARD CARE. THE STUDY AIMED TO DETERMINE IF ACHIEVING NEAR NORMALIZATION OF GLUCOSE LEVELS IMMEDIATELY AFTER DIAGNOSIS COULD PRESERVE PANCREATIC BETA CELL FUNCTION. DESPITE ACHIEVING EXCELLENT GLUCOSE CONTROL, THE INTENSIVE MANAGEMENT GROUP DID NOT SHOW A SIGNIFICANT DIFFERENCE IN PANCREATIC C-PEPTIDE SECRETION DECLINE AT 52 WEEKS COMPARED TO THE STANDARD CARE GROUP, SUGGESTING THAT THIS APPROACH DID NOT IMPACT THE PRESERVATION OF BETA CELL FUNCTION IN THE STUDIED POPULATION.A STUDY COMPARING INTRAVITREAL AFLIBERCEPT TREATMENT TO A SHAM PROCEDURE IN INDIVIDUALS WITH MODERATE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY (NPDR) WITHOUT CENTER-INVOLVED DIABETIC MACULAR EDEMA (CI-DME) REVEALED THAT OVER FOUR YEARS, AFLIBERCEPT SIGNIFICANTLY REDUCED THE LIKELIHOOD OF DEVELOPING VISION-THREATENING COMPLICATIONS COMPARED TO THE SHAM PROCEDURE. HOWEVER, DESPITE ANATOMICAL IMPROVEMENT, THERE WAS NO SIGNIFICANT DIFFERENCE IN VISUAL ACUITY BETWEEN THE TWO GROUPS. THE STUDY SUGGESTS THAT USING AFLIBERCEPT PREVENTIVELY IN PATIENTS WITH NPDR WITHOUT CI-DME MAY NOT BE GENERALLY NECESSARY BASED ON THE OBSERVED OUTCOMES.JCHR'S INVOLVEMENT IN DIABETES STUDIES CONTINUES TO EXPAND AS IT SOLIDIFIED ITS REPUTATION AS THE PREMIERE COORDINATING CENTER WORLDWIDE FOR DIABETES DEVICE STUDIES.
Expenses $37,585,083 · Grants $911,714 · Revenue $17,927,381
As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
Roy BeckROY BECK
MEDICAL DIRECTOR (PRESIDENT THRU 09/23)
- Total calculated
- $574,043
- From this org
- $486,749
- From related orgs
- $0
- Other
- $87,294
- Hours/week
- 40 + 1 related
Schedule J breakdown matched by us
- Base
- $486,749
- Bonus
- $0
- Other
- $0
- Deferred
- $22,838
- Nontaxable benefits
- $64,456
- Filer's total
- $574,043
-
Dana BallDANA BALL
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1 + 1 related
-
Neil BresslerNEIL BRESSLER
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1 + 1 related
-
Anne LindbladANNE LINDBLAD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1 + 1 related
-
Shan ShikarpuriSHAN SHIKARPURI
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1 + 1 related
-
Erica VogtERICA VOGT
CHIEF FINANCIAL OFFICER
- Total calculated
- $238,794
- From this org
- $221,629
- From related orgs
- $0
- Other
- $17,165
- Hours/week
- 40 + 1 related
Schedule J breakdown matched by us
- Base
- $221,629
- Bonus
- $0
- Other
- $0
- Deferred
- $9,500
- Nontaxable benefits
- $7,665
- Filer's total
- $238,794
-
Adam GlassmanADAM GLASSMAN
PRESIDENT (EXECTIVE DIRECTOR THRU 09/23)
- Total calculated
- $377,040
- From this org
- $332,525
- From related orgs
- $0
- Other
- $44,515
- Hours/week
- 40 + 1 related
Schedule J breakdown matched by us
- Base
- $332,525
- Bonus
- $0
- Other
- $0
- Deferred
- $15,000
- Nontaxable benefits
- $29,515
- Filer's total
- $377,040
-
Jeannie PerkinsJEANNIE PERKINS
CHIEF RESEARCH COMPLIANCE OFFICER
- Total calculated
- $211,143
- From this org
- $190,500
- From related orgs
- $0
- Other
- $20,643
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $190,500
- Bonus
- $0
- Other
- $0
- Deferred
- $8,400
- Nontaxable benefits
- $12,243
- Filer's total
- $211,143
-
Craig KollmanCRAIG KOLLMAN
DIRECTOR OF BIOSTATISTICS
- Total calculated
- $282,778
- From this org
- $243,094
- From related orgs
- $0
- Other
- $39,684
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $243,094
- Bonus
- $0
- Other
- $0
- Deferred
- $11,250
- Nontaxable benefits
- $28,434
- Filer's total
- $282,778
-
Allison AyalaALLISON AYALA
BIOSTATISTICIAN IV
- Total calculated
- $204,860
- From this org
- $185,529
- From related orgs
- $0
- Other
- $19,331
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $185,529
- Bonus
- $0
- Other
- $0
- Deferred
- $8,150
- Nontaxable benefits
- $11,181
- Filer's total
- $204,860
-
B Michele MeliaB MICHELE MELIA
BIOSTATISTICIAN V
- Total calculated
- $244,134
- From this org
- $224,250
- From related orgs
- $0
- Other
- $19,884
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $224,250
- Bonus
- $0
- Other
- $0
- Deferred
- $9,713
- Nontaxable benefits
- $10,171
- Filer's total
- $244,134
-
Peter CalhounPETER CALHOUN
BIOSTATISTICIAN IV
- Total calculated
- $222,507
- From this org
- $202,727
- From related orgs
- $0
- Other
- $19,780
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $202,727
- Bonus
- $0
- Other
- $0
- Deferred
- $9,250
- Nontaxable benefits
- $10,530
- Filer's total
- $222,507
-
Raymond KrakerRAYMOND KRAKER
EPIDEMIOLOGIST IV
- Total calculated
- $208,630
- From this org
- $168,949
- From related orgs
- $0
- Other
- $39,681
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $168,949
- Bonus
- $0
- Other
- $0
- Deferred
- $8,300
- Nontaxable benefits
- $31,381
- Filer's total
- $208,630
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
- 3 · Compensation committee
- 3 · Compensation survey or study
- 3 · Approval by the board or compensation committee
Answered no
- 4a · Severance or change-of-control payment
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
- 5a · Pay contingent on this organization's revenues
- 5b · Pay contingent on a related organization's revenues
- 6a · Pay contingent on this organization's net earnings
- 6b · Pay contingent on a related organization's net earnings
- 7 · Other non-fixed payments
- 8 · Paid under the initial-contract exception
The filer's explanations (Part III)
- PART I, LINE 3
- THE BOARD OF DIRECTORS SHALL ANNUALLY REVIEW AND APPROVE THE COMPENSATION OF THE CORPORATE OFFICERS, ANY KEY EMPLOYEES (AS DEFINED BY THE IRS), AND THE NEXT FIVE HIGHEST COMPENSATED EMPLOYEES AS LISTED ON THE ORGANIZATION'S PRIOR YEAR FORM 990. IT IS THE BOARD'S INTENTION THAT THIS POLICY AND ITS ASSOCIATED PROCEDURES WILL MEET THE REBUTTABLE PRESUMPTION TEST UNDER IRC 4958 AND TREASURY REGULATION 53.4958-6. THE PURPOSE OF THE ANNUAL REVIEW IS TO ENSURE THAT THE COMPENSATION PROGRAM FALLS WITHIN A REASONABLE RANGE OF COMPETITIVE PRACTICES FOR COMPARABLE POSITIONS AMONG SIMILARLY SITUATED ORGANIZATIONS. THE BOARD WILL KEEP ROBUST MINUTES OF ITS DELIBERATIONS AND DECISIONS, THE PRESIDENT'S REPORTS, THE CORPORATE TREASURER'S REPORTS, AND ANY OTHER SUPPORTING DOCUMENTATION THAT IT RELIES ON FOR ITS COMPENSATION DECISIONS. ALL THESE DOCUMENTS WILL BE DELIVERED TO THE CORPORATE SECRETARY PROMPTLY AFTER THE BOARD MEETING FOR ENTRY INTO THE CORPORATE BOOKS AND RECORDS.
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
-
JAEB CENTER RESEARCH TRUST INC
$911,714
GENERAL SUPPORT
Activities outside the United States
From Schedule F of this return, as filed.
- Offices (line 3c)
- 0
- Employees, agents and contractors (line 3c)
- 8
- Expenditures and investments (line 3c)
- $213,759
At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.
Activities by region (Part I)
| Region | Offices | Employees | Activity | Specific services | Expenditures |
|---|---|---|---|---|---|
| NORTH AMERICA | 0 | 3 | PROGRAM SERVICES | CLINICAL RESEARCH SITES CONTRACTED TO ENROLL PATIENTS AND CONDUCT RESEARCH ACTIVITIES | $46,656 |
| EUROPE (INCLUDING ICELAND & GREENLAND) | 0 | 4 | PROGRAM SERVICES | CLINICAL RESEARCH SITES CONTRACTED TO ENROLL PATIENTS AND CONDUCT RESEARCH ACTIVITIES | $153,123 |
| MIDDLE EAST AND NORTH AFRICA | 0 | 1 | PROGRAM SERVICES | CLINICAL RESEARCH SITES CONTRACTED TO ENROLL PATIENTS AND CONDUCT RESEARCH ACTIVITIES | $13,980 |
- Transferred property to a foreign corporation during the year (line 1)
- No
- Had an interest in a foreign trust (line 2)
- No
- Owned an interest in a foreign corporation (line 3)
- No
- Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
- No
- Owned an interest in a foreign partnership (line 5)
- No
- Had operations in or related to a boycotting country (line 6)
- No
Related organizations on this return
Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.
-
JAEB CENTER RESEARCH TRUST INC
501(C)(3) · SUPPORT · FL
Provenance
- Return type
- form_990
- Tax year
- 2023
- Filed
- 2 April 2024
- IRS schema version
- 2023v5.0
- Source object
- 202430969349301203
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.